



June 2009 ACVIM Forum and Canadian Veterinary Medical Association www.alcherabio.com

AlcheraBio Visits Montreal

The joint meeting of ACVIM and the Canadian Veterinary Medical Association offers the opportunity for practitioners, researchers, and industry – not only from North America but from around the world as well – to share what's emerging in animal health.

AlcheraBio is pleased to be attending this important event, represented by AlcheraBio's Chief Operating Officer Dr. Johnny A. Jacobsen. To learn more about Dr. Jacobsen, see page 2. To arrange a meeting with Dr. Jacobsen at ACVIM to discuss AlcheraBio's services, please call him at 732-407-8249 or email jajacobsen@alcherabio.com. He'll have his BlackBerry®!

Outsourcing in the Animal Health Industry

One of the strongest trends in the animal health industry is outsourcing, which is playing an increasingly important role in developing and commercializing products for use in animals. AlcheraBio was established in 2001 to provide services and consulting for the animal health industry.

As a full-service clinical Contract Research Organization, we offer our clients services required for drafting development plans and protocols; interacting with regulatory agencies; conducting early stage and pivotal clinical studies, including data management and final report writing; and assembling regulatory submissions. We have experienced, in-house SAS programming and can provide QA (quality assurance) staff for all aspects of development (GLP/GCP). We also provide the services needed to conduct post-marketing studies. Our clinical research services are available in the US and Europe. The company was acquired in 2008 and is now a subsidiary of Argenta, which is a global leader in animal health manufacturing, formulations, and related services. See page 2 for more information on services from Argenta.

Attention Practitioners: Do you think it might be interesting to participate in clinical trials of animal health products?

No matter how large or small a given clinical study is, finding the right clinicians to serve as study investigators is vital to maintaining high quality and ensuring that enrollment, timing objectives, and other study parameters are met. Veterinarians who take part in clinical studies generally find them to be an exciting added dimension to clinical practice, as well as a service to their clients. Investigators who qualify to participate in a given study are trained thoroughly. In the case of studies conducted under GCP guidelines, study monitors are assigned to perform site visits to help with documenting the study properly and meeting all requirements.

If you are a practitioner interested in learning more about the opportunities, responsibilities, and benefits for you and your patients of taking part in clinical studies, please contact these AlcheraBio monitors: Michele Nichols (mnichols@alcherabio.com) or Georgiana Syby (gsyby@alcherabio.com) or call AlcheraBio at 732 205-0192.

To learn about the other types of services from AlcheraBio, call us at 732-205-0192 or visit our website at www.alcherabio.com. To inquire about Quality Assurance support, please call Nick Meo at 732-205-0192. To read more about our data management services, see page 2.

Data Management Services from AlcheraBio

Many of our clients turn to AlcheraBio for data management to support their pivotal and postmarketing studies. We've developed a data management system customized to meet the needs of the animal health community. It's a double data entry system with an audit trail, secure off-site backup, and other critical features, including an easy system for generating and resolving queries. Our in-house SAS programmer can prepare listings and reports, perform edit checks, create derived data sets, generate efficacy and safety summary reports, produce graphs, design layouts for final report tables and perform full data analysis according to the Sponsor's strategic analysis plan.

To learn more about AlcheraBio's data management services please contact Michele Rivera or Dr. Johnny Jacobsen at 732 205-0192.



Formulations and Manufacturing Services Available from Argenta, AlcheraBio's Parent Company

AlcheraBio LLC is a subsidiary of Argenta, which is headquartered in New Zealand and is the world's first Contract Development and Manufacturing Organization (CDMO) dedicated to animal health. Argenta offers formulation and analytical development services, and manufactures clinical trial material and commercial animal health products to cGMP. Argenta exports its clients' products to more than 60 countries, including the US and European nations. For more information, see www.argenta.co.nz or contact Dr. Jane Eagleson, Argenta business development manager and AlcheraBio president, at: 011 64 9 250 3192 (office) or email jane.eagleson@argenta.co.nz.



Meet Dr. Johnny Jacobsen, AlcheraBio Chief Operating Officer

Dr. Jacobsen received his DVM degree from the University of Saskatchewan and his MSc degree in applied parasitology from the University of Calgary.

After completing his veterinary education and establishing a mixed animal practice in Alberta, Canada, Dr. Jacobsen joined the technical services organization of Merck AgVet, now Merial, in positions of increasing responsibility. He oversaw more than 45 field trials and established critical relationships with key leaders in the veterinary community. Later, as an executive in Merck AgVet's and Merial's global marketing and strategic planning organizations, Dr. Jacobsen developed Statements of Interest and Market Opportunity Reports that resulted in new product development projects. He led global cross-functional development and marketing teams in support of the launches of two major cattle products and managed extensive product portfolios, interfacing with manufacturing, clinical development, regulatory affairs, and worldwide subsidiaries. Immediately prior to joining AlcheraBio, Dr. Jacobsen was at Merck & Co., Inc. where he was a global brand leader in several therapeutic areas in the Global Human Health organization. Dr. Jacobsen joined AlcheraBio in February 2009.